A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Synonyms :
Class :
COVID-19, Monoclonal Antibodies
Brand Name :
Synonyms :
Class :
COVID-19, Monoclonal Antibodies
Dosage forms & Strengths:Â
Adult:Â
Injectable solution:Â
175mg/2mLÂ
November 30, 2022- It is not authorized in any U.S. region due to the prevalence of SARS-CoV-2 variants that are resistant to the drug.
Indication
February 11, 2022- The FDA issued an emergency use authorization (EUA) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and children above 12 years and weighing more than 40 kg.
175 mg administered intravenously over at least 30 seconds.
To be given within seven days after the beginning of symptoms or immediately if direct testing for SARS-CoV-2 is positive.
Dose Adjustments
Renal Impairment
Dialysis or any level of severity: No Dosage Modification Is Suggested
It is known that monoclonal antibodies (mAbs) with molecular weights greater than 69 kDa do not undergo renal elimination. This is not expected to have any effect on the pharmacokinetics of bebtelovimab.
Hepatic Impairment
Mild: No dose modification is advised.
Moderate-to-severe: Not investigated
November 30, 2022- It is not authorized in any U.S. region due to the prevalence of SARS-CoV-2 variants that are resistant to the drug.
Indication
February 11, 2022- The FDA has granted an emergency use authorization (EUA) for treating mild-to-moderate coronavirus illness 2019 (COVID-19) in adults and children older than 12 who weigh less than 40 kg.
< 12 years: Not authorized.
≥12 years (weight ≥40 kg): 175 mg given intravenously in a single dose over at least 30 seconds.
If direct SARS-CoV-2 virus testing is positive and symptoms appear within seven days, start treatment as soon as possible
Dose Adjustments
Renal Impairment
Dialysis or any level of severity: No Dosage Modification Is Suggested
It is known that monoclonal antibodies (mAbs) with molecular weights greater than 69 kDa do not undergo renal elimination. This is not expected to have any effect on the pharmacokinetics of bebtelovimab.
Hepatic Impairment
Mild: No dose modification is advised.
Moderate-to-severe: Not investigated
<1%:Â
RashÂ
Reactions due to infusionÂ
PruritisÂ
Bebtelovimab is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
The data is not sufficient for the usage of the drug during pregnancy. It should only be used if the potential benefits should outweigh the potential risks to the mother and fetus.Â
Breastfeeding warnings:Â Â
No data is available regarding the presence of the drug in breast milk.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: bebtelovimabÂ
Pronounced: beyb-tey-loh-vih-mabÂ
Why do we use bebtelovimab?Â
Bebtelovimab belongs to the category of monoclonal antibodies. It is an investigational drug used for the treatment of SARS-CoV-2.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
